NCT03390894|Recruiting
Loading search results
Sponsor study identifier
Secondary identifiers
EUDRACT_NUMBER
NIH
observational
8,000
1 country
73
Study Start
January 18, 2018
Actual (reported)Primary Completion
January 2047
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
January 2048
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
This is a multicenter, cohorts study to collect information from patients diagnosed with early-stage invasive breast cancer who have been previously included in a neoadjuvant or adjuvant clinical trial of the GEICAM group. Patients will be included in this study from the moment of completion of the follow-up of the studies of origin and will be followed for approximately 30 years
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
January 2048
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
December 29, 2017
Actual (reported)January 4, 2018
Actual (reported)January 18, 2018
Actual (reported)January 2047
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
January 2048
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Event Free Survival (EvFS) in neoadjuvant studies.
The EvFS, is defined as the time from the randomization of the patients in the studies of origin, to the date of one of the following events: * Disease progression during neoadjuvant treatment. * Disease relapse (local, regional or distant) after curative surgery. * Second primary tumors * Death due to any cause.
Throughout the whole follow up. Up to 30 years from the beginning of the Study approximately.
Disease Free Survival (DFS) in adjuvant studies.
DFS is defined as the time from the date of randomization of patients in the studies of origin, to the date of one of the following events: * Disease relapse (local, regional or distant) after curative surgery. * Second primary tumors * Death due to any cause.
Throughout the whole follow up. Up to 30 years from the beginning of the Study approximately.
Overall Survival (OS).
Throughout the whole follow up. Up to 30 years from the beginning of the Study approximately.
These entries preserve how the registry describes the intervention. Their treatment roles are shown separately from molecular identities.
Formulated product
Aromasil 25 mg comprimidos recubiertos
The registry describes a specific formulation. Its exact chemical ingredients and approval status require separate evidence.
COATED TABLET
View registry recordFormulated product
Gemcitabina Accord 2000 mg polvo para solución para perfusión
The registry describes a specific formulation. Its exact chemical ingredients and approval status require separate evidence.
SOLUTION FOR INFUSION
View registry recordFormulated product
Xeloda 500 mg film-coated tablets
The registry describes a specific formulation. Its exact chemical ingredients and approval status require separate evidence.
FILM-COATED TABLET
View registry recordFormulated product
LAPATINIB
The registry describes a specific formulation. Its exact chemical ingredients and approval status require separate evidence.
FILM-COATED TABLET
View registry recordFormulated product
TAXOTERE 20 mg/0.5 ml concentrate and solvent for solution for infusion
The registry names these ingredients. The formulation’s exact chemical form has not been confirmed.
Aromasil 25 mg comprimidos recubiertos
Named ingredient: exemestane
View registry recordGemcitabina Accord 2000 mg polvo para solución para perfusión
Named ingredient: Gemcitabine
View registry recordXeloda 500 mg film-coated tablets
Named ingredient: Capecitabine
View registry recordLAPATINIB
Named ingredient: Lapatinib
View registry recordTAXOTERE 20 mg/0.5 ml concentrate and solvent for solution for infusion
Named ingredient: Docetaxel
View registry recordOfev 100 mg soft capsules
Named ingredient: nintedanib
View registry recordMyocet liposomal 50 mg powder, dispersion and solvent for concentrate for dispersion for infusion.
Patients with invasive breast cancer (early stages) included in neoadjuvant and adjuvant clinical trials with GEICAM's participation.
Complejo Hospitalario de Navarra
Pamplona, Navarre, Spain
Hospital San Agustín Avilés
Avilés, Principality of Asturias, Spain
Hospital Universitario de Canarias
San Cristóbal de La Laguna, Tenerife, Spain
Centro Oncológico de Galicia
A Coruña, Spain
Study Director
Complejo Hospitalario de Especialidades Virgen de la Victoria
Study Director
Hospital General Universitario Gregorio Marañon
First Submitted
December 29, 2017
First Posted
January 4, 2018
Study Start
January 18, 2018
Actual (reported)Primary Completion
January 2047
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
The registry describes a specific formulation. Its exact chemical ingredients and approval status require separate evidence.
SOLUTION FOR INFUSION
Formulated product
Ofev 100 mg soft capsules
The registry describes a specific formulation. Its exact chemical ingredients and approval status require separate evidence.
CAPSULE, SOFT
View registry recordFormulated product
Myocet liposomal 50 mg powder, dispersion and solvent for concentrate for dispersion for infusion.
The registry describes a specific formulation. Its exact chemical ingredients and approval status require separate evidence.
DISPERSION FOR INFUSION
View registry recordFormulated product
Carboplatin 10 mg/ml Concentrate for Solution for Infusion
The registry describes a specific formulation. Its exact chemical ingredients and approval status require separate evidence.
SOLUTION FOR INFUSION
View registry recordFormulated product
Paclitaxel Hospira 6 mg/ml concentrado para solución para perfusión EFG
The registry describes a specific formulation. Its exact chemical ingredients and approval status require separate evidence.
SOLUTION FOR INFUSION
View registry recordFormulated product
Faslodex 250 mg solution for injection.
The registry describes a specific formulation. Its exact chemical ingredients and approval status require separate evidence.
SOLUTION FOR INJECTION
View registry recordFormulated product
Herceptin 150 mg powder for concentrate for solution for infusion
The registry describes a specific formulation. Its exact chemical ingredients and approval status require separate evidence.
SOLUTION FOR INFUSION
View registry recordNamed ingredient: Doxorubicin hydrochloride
Carboplatin 10 mg/ml Concentrate for Solution for Infusion
Named ingredient: Carboplatin
View registry recordPaclitaxel Hospira 6 mg/ml concentrado para solución para perfusión EFG
Named ingredient: Paclitaxel
View registry recordFaslodex 250 mg solution for injection.
Named ingredient: Fulvestrant
View registry recordHerceptin 150 mg powder for concentrate for solution for infusion
Named ingredient: Trastuzumab
View registry recordContact the study team to confirm eligibility.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Complejo Hospitalario A Coruña
A Coruña, Spain
Complejo Hospitalario Universitario de Albacete
Albacete, Spain
Hospital General Universitario de Alicante
Alicante, Spain
Hospital General Universitario de Elche
Alicante, Spain
Hospital General Universitario de Elda
Alicante, Spain
Hospital Virgen De Los Lirios
Alicante, Spain
Hospital Infanta Cristina
Badajoz, Spain
Hospital Universitari Germans Trias i Pujol
Badalona, Spain
Consorci Sanitari de Terrassa
Barcelona, Spain
Hospital Clinic i Provincial
Barcelona, Spain
Hospital de la Santa Creu i Sant Pau
Barcelona, Spain
Hospital del Mar
Barcelona, Spain
Hospital Universitario Mutua Terrassa
Barcelona, Spain
Instituto Catalán Oncología Barcelona Hospital Duran I Reynalds
Barcelona, Spain
Hospital Universitario de Basurto
Bilbao, Spain
Hospital Universitario de Burgos
Burgos, Spain
Complejo Especialidades de Jerez de la Frontera
Cadiz, Spain
Hospital Universitario Puerta del Mar
Cadiz, Spain
Complejo Hospitalario de Castellón
Castelló, Spain
Hospital Universitario Reina Sofía
Córdoba, Spain
Hospital Virgen De La Luz
Cuenca, Spain
Hospital Universitario de Cruces
Donostia / San Sebastian, Spain
Hospital Universitario Donostia
Donostia / San Sebastian, Spain
Onkologikoa
Donostia / San Sebastian, Spain
Instituto Catalán de Oncología Gerona Hospital Dr. Josep Trueta
Girona, Spain
Hospital Universitario San Cecilio
Granada, Spain
Hospital Universitario Virgen De Las Nieves
Granada, Spain
Hospital Universitario de Guadalajara
Guadalajara, Spain
Complejo Hospitalario de Especialidades Juan Ramón Jiménez
Huelva, Spain
Complejo Hospitalario de Jaén
Jaén, Spain
Complejo Hospitalario Universitario de Gran Canaria Dr. Negrín
Las Palmas de Gran Canaria, Spain
Hospital de León
León, Spain
Hospital Universitario Lucus Augusti
Lugo, Spain
Hopsital Clínico San Carlos
Madrid, Spain
Hospital de Mostoles
Madrid, Spain
Hospital general Universitario Gregorio Marañón
Madrid, Spain
Hospital Madrid Montepricipe
Madrid, Spain
Hospital Universitario 12 de Octubre
Madrid, Spain
Hospital Universitario Fuenlabrada
Madrid, Spain
Hospital Universitario Fundación Alcorcón
Madrid, Spain
Hospital Universitario La Paz
Madrid, Spain
Hospital Universitario La Princesa
Madrid, Spain
Hospital Universitario Ramón y Cajal
Madrid, Spain
Hospital Universitario Severo Ochoa
Madrid, Spain
MD Anderson Cancer Center
Madrid, Spain
ALTHAIA Xarxa Asistencial Universitària Manresa
Manresa, Spain
Hospital Regional de Málaga Carlos Haya
Málaga, Spain
Hospital Universitario Virgen de la Victoria
Málaga, Spain
Hospital Clínico Universitario Virgen de la Arrixaca
Murcia, Spain
Hospital General Universitario José María Morales Meseguer
Murcia, Spain
Hospital santa María Naí
Ourense, Spain
Complejo Hospitalario de Palencia
Palencia, Spain
Hospital Álvaro Cunqueiro
Pontevedra, Spain
Corporación Sanitaria Parc Taulí
Sabadell, Spain
Hospital Universitario de Salamanca
Salamanca, Spain
Hospital Nuestra Señora De La Candelaria
Santa Cruz de Tenerife, Spain
Hospital Universitario de Valme
Seville, Spain
Hospital Universitario Sant Joan De Reus
Tarragona, Spain
Hospital Virgen de la Salud
Toledo, Spain
Fundación Instituto Valenciano de Oncología
Valencia, Spain
Hospital Arnau Vilanova
Valencia, Spain
Hospital Clínico Universitario de Valencia
Valencia, Spain
Hospital de Sagunto
Valencia, Spain
Hospital General Universitario de Valencia
Valencia, Spain
Hospital Universitari i Politécnic La Fe
Valencia, Spain
Hospital Universitario Dr. Peset Aleixandre
Valencia, Spain
Hospital de Txagorritxu
Vitoria-Gasteiz, Spain
Hospital Clínico Universitario de Zaragoza Lozano Blesa
Zaragoza, Spain
Hospital Universitario Miguel Servet
Zaragoza, Spain
Study Completion
January 2048
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
October 13, 2026
Record last verified: 2026-10
Study fields come from the primary record; confirmed relationships can use other sources. Selecting a record here changes its provenance and downloads, without replacing the displayed study fields.
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: